Arrow-right Camera

The Spokesman-Review Newspaper The Spokesman-Review

Spokane, Washington  Est. May 19, 1883
Partly Cloudy Night 27° Partly Cloudy
News >  Business

GlaxoSmithKline to spend $5.1B on cancer drugmaker Tesaro

In this July 24, 2013 photo, a security guard walks in front of the GlaxoSmithKline building in Shanghai, China. (Eugene Hoshiko / Associated Press)
In this July 24, 2013 photo, a security guard walks in front of the GlaxoSmithKline building in Shanghai, China. (Eugene Hoshiko / Associated Press)
Associated Press

Shares of Tesaro soared Monday after GlaxoSmithKline said it would pay about $5.1 billion in cash to buy the cancer drugmaker.

Glaxo plans to pay $75 per share for Tesaro, which makes the ovarian cancer treatment Zejula. That represents a premium of more than 60 percent to the stock’s $46.38 closing price Friday. The total deal price includes Tesaro’s net debt.

Glaxo CEO Emma Walmsley said in a statement that the deal will accelerate growth of the British drugmaker’s oncology business.

Zejula brought in $166 million in revenue in the first nine months of this year, with third-quarter sales growing more than 60 percent.

Glaxo expects the deal to close in the first quarter.

Shares of Waltham, Massachusetts-based Tesaro Inc. jumped nearly 59 percent to $73.60 in morning trading.

The Spokesman-Review Newspaper

Local journalism is essential.

Give directly to The Spokesman-Review's Northwest Passages community forums series -- which helps to offset the costs of several reporter and editor positions at the newspaper -- by using the easy options below. Gifts processed in this system are not tax deductible, but are predominately used to help meet the local financial requirements needed to receive national matching-grant funds.

Subscribe to the Coronavirus newsletter

Get the day’s latest Coronavirus news delivered to your inbox by subscribing to our newsletter.


Annual health and dental insurance enrollment period open now

 (Courtesy Washington Healthplanfinder)
Sponsored

2020 has been a stressful year for myriad reasons.